Ironwood Acquires VectivBio for $1B to Expand Rare Gastrointestinal Pipeline.

Ironwood Pharmaceuticals has agreed to acquire Swiss biotech VectivBio in an all-cash deal worth an estimated $1bn, expanding its rare gastrointestinal pipeline. The Boston-based drugmaker will purchase the European firm for $17 per share, an 80% premium to the previous 90-day volume-weighted average. The deal follows board approval from both sides.